Wealth Enhancement Advisory Services LLC Purchases 80,087 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Wealth Enhancement Advisory Services LLC increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 17.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 550,613 shares of the biopharmaceutical company's stock after buying an additional 80,087 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Bristol Myers Squibb were worth $33,582,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Wealthspire Advisors LLC increased its position in shares of Bristol Myers Squibb by 0.6% during the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock valued at $1,622,000 after purchasing an additional 170 shares during the last quarter. Bedel Financial Consulting Inc. increased its position in shares of Bristol Myers Squibb by 3.2% during the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock valued at $340,000 after purchasing an additional 175 shares during the last quarter. King Wealth Management Group increased its position in shares of Bristol Myers Squibb by 2.6% during the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock valued at $413,000 after purchasing an additional 182 shares during the last quarter. Thoroughbred Financial Services LLC increased its position in shares of Bristol Myers Squibb by 1.1% during the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock valued at $1,004,000 after purchasing an additional 190 shares during the last quarter. Finally, Marcum Wealth LLC grew its stake in shares of Bristol Myers Squibb by 1.0% during the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after acquiring an additional 193 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Trading Up 0.1%

Bristol Myers Squibb stock traded up $0.03 during trading hours on Friday, reaching $46.87. The company had a trading volume of 47,283,703 shares, compared to its average volume of 12,989,833. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The company has a 50-day moving average price of $48.20 and a 200 day moving average price of $54.32. The firm has a market cap of $95.38 billion, a price-to-earnings ratio of 17.55, a P/E/G ratio of 1.39 and a beta of 0.38. Bristol Myers Squibb Company has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business's quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($4.40) EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Activity

In other Bristol Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol Myers Squibb stock in a transaction dated Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.09% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price target on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Argus upgraded Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Jefferies Financial Group cut their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.